Dr. V. Prasada Raju
#466Managing Director
55
Age
23y
Exp
4y
Tenure
5/10
Risk
🎓 not found · not found
📜 PhD Chemistry,PG Dip Patent Law · JNTUH College of Engineering Hyderabad (PhD Chemistry); NALSAR University of Law Hyderabad (PG Dip Patent Law); IIM Calcutta (SMP); Illinois Institute of Technology (Material Sciences)
🏛️ None
CompensationTBP
Personality
6
Open
7
Cons
4
Extr
5
Agre
3
Neur
Cohance Life
Healthcare · Mid Cap
High Growth · Performance-Driven
About
Dr. V. Prasada Raju is the Managing Director of Cohance Life, a Mid Cap company in the Healthcare sector with a market cap of ₹11K Cr. A Pragmatic leader with 23 years of experience, he is known for data-driven decision-making and aggressive acquirer strategy. Maintains a disciplined focus on scaling CDMO capabilities while emphasizing quality systems and technical regulatory standards.
FAQ
What is Dr. V. Prasada Raju's leadership style?
Dr. V. Prasada Raju is classified as a Pragmatic leader. He is data-driven in decision-making, with a category creator motivation and startup-speed pace of execution.
What is Dr. V. Prasada Raju's educational background?
Dr. V. Prasada Raju holds a not found from not found and a PhD Chemistry,PG Dip Patent Law from JNTUH College of Engineering Hyderabad (PhD Chemistry); NALSAR University of Law Hyderabad (PG Dip Patent Law); IIM Calcutta (SMP); Illinois Institute of Technology (Material Sciences).
Who is the CEO of Cohance Life?
Dr. V. Prasada Raju is the Managing Director of Cohance Life. He has been with the company for 4 years and in the current role for 4 years.
Leadership DNA
ArchetypePragmatic
MotivationCategory Creator
CrisisRestructurer
DecisionData-Driven
GrowthAggressive Acquirer
PeopleNumbers Driven
InnovationFast-Follower
PaceStartup-Speed
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusOperational Excellence
OrientationDeep Specialist
Leadership Evidence
“Maintains a disciplined focus on scaling CDMO capabilities while emphasizing quality systems and technical regulatory standards.”
⚡ Crisis●●●●○
As MD of Cohance Life, he spearheaded the integration and restructuring of three distinct CDMO entities (Manudhan, Stride, and Vivin) into a unified, focused platform.
🎯 Motivation●●●○○
His focus at Cohance is on building a specialized, high-end CDMO platform that differentiates itself through complex chemistry rather than just generic volume.
👥 People●●●●○
His professional reputation is built on operational excellence, data-driven decision-making, and rigorous process optimization in the pharmaceutical manufacturing space.
📈 Growth●●●●●
Cohance Life Sciences was formed specifically through the strategic acquisition and consolidation of three separate companies under the Advent International portfolio.
💡 Innovation●●●●○
As a CDMO and API manufacturer, the company focuses on process chemistry excellence and scaling complex generic molecules rather than pioneering new drug discovery.
🏃 Pace●●●○○
Operating in the high-growth CDMO space requires aggressive capacity expansion and rapid project turnaround to meet global pharmaceutical client timelines.
🌱 Purpose●●●○○
The company emphasizes high-quality healthcare access and sustainable manufacturing practices as key pillars of its CDMO service offering.
🏷️ Brand●●●●○
The company is positioned as a specialized, high-capability partner for complex chemical synthesis and regulatory-compliant manufacturing.
🤝 Customer●●●●●
The company operates primarily as a B2B partner providing APIs and intermediate solutions to global pharmaceutical enterprises.
💼 Employer●●●○○
The performance-driven culture inherent in the specialty chemicals and API manufacturing sector demands high technical precision and rigorous output targets.
📋 Mandate
Needs to scale complex chemical manufacturing processes while maintaining rigorous global quality compliance standards.
🏢 Culture●●●○○
High-growth CDMO operations requiring rigorous quality compliance and efficient delivery cycles.
Financials
Revenue FY25₹1K Cr
PAT FY25₹268 Cr
Rev CAGR 5Y-3.6%
OPM28%
NPM22.9%
ROE15.8%
ROCE12.3%
P/E58.5
Fwd P/E28.8
P/B3
D/E11.5
Promoter64%
Institutional24.8%
Mkt Cap₹11K Cr
Compensation
To Be Published
Data being verified from audited reports
